Notice2024-04425
Government-Owned Inventions; Availability for Licensing
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
March 4, 2024
Issuing agencies
Health and Human Services DepartmentNational Institutes of Health
Abstract
The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.
Full Text
<html>
<head>
<title>Federal Register, Volume 89 Issue 43 (Monday, March 4, 2024)</title>
</head>
<body><pre>
[Federal Register Volume 89, Number 43 (Monday, March 4, 2024)]
[Notices]
[Page 15599]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2024-04425]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The invention listed below is owned by an agency of the U.S.
Government and is available for licensing to achieve expeditious
commercialization of results of federally-funded research and
development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing.
FOR FURTHER INFORMATION CONTACT: Brian Bailey, Ph.D., at 240-669-5128
or 301-201-9217, or by email at <a href="/cdn-cgi/l/email-protection#d3b1b1b2babfb6aa93beb2babffdbdbabbfdb4bca5"><span class="__cf_email__" data-cfemail="137171727a7f766a537e727a7f3d7d7a7b3d747c65">[email protected]</span></a>. Licensing
information may be obtained by communicating with the Technology
Transfer and Intellectual Property Office, National Institute of
Allergy and Infectious Diseases, 5601 Fishers Lane, Rockville, MD
20852: tel. 301-496-2644. A signed Confidential Disclosure Agreement
will be required to receive copies of unpublished information related
to the invention.
SUPPLEMENTARY INFORMATION: Technology description follows:
SARS-CoV-2 Pseudotyping Plasmids for Cutting-Edge Studies
Description of Technology
NIAID scientists have developed plasmids that allow for production
of pseudoviruses expressing SARS-CoV-2 spike protein. As SARS-CoV-2 is
a lethal airborne virus, it must be handled in high-containment
Biosafety Level 3 (BSL-3) laboratories that require strict airflow,
ventilation and decontamination procedures. The pseudotyping plasmids
of this invention provide a secure platform for exploring SARS-CoV-2
dynamics without the need for high-risk handling of live virus and
ensure a controlled environment for scientists to study SARS-CoV-2 more
expeditiously in standard Biosafety Level 2 (BSL-2) laboratories. The
plasmids can be used for diverse SARS-CoV-2 research applications,
including the study of newly emerging or potential future variants of
interest.
This technology is available for licensing for commercial
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as
well as for further development and evaluation under a research
collaboration.
Potential Commercial Applications
<bullet> Research material that can be used in the development of
neutralization assays
Competitive Advantages
<bullet> Expedite SARS-CoV-2 related experiments by enabling them
to be conducted in laboratories with a lower Biosafety Level (BSL-2)
than that required for handling SARS-CoV-2 (BSL-3)
Development Stage
<bullet> Research material.
Inventors
Dr. Barney Graham, Dr. Lingshu Wang, Dr. John Mascola, Dr.
Kizzmekia Corbett, all of NIAID.
Intellectual Property
HHS Reference No. E-223-2020-0.
Licensing Contact
To license this technology, please contact Brian Bailey, Ph.D.;
240-669-5128 or 301-201-9217; <a href="/cdn-cgi/l/email-protection#cfadadaea6a3aab68fa2aea6a3e1a1a6a7e1a8a0b9"><span class="__cf_email__" data-cfemail="8eececefe7e2ebf7cee3efe7e2a0e0e7e6a0e9e1f8">[email protected]</span></a>, and reference E-
223-2020.
Dated: February 14, 2024.
Surekha Vathyam,
Deputy Director, Technology Transfer and Intellectual Property Office,
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2024-04425 Filed 3-1-24; 8:45 am]
BILLING CODE 4140-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on March 4, 2024.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.